Antihistamine shows promise for remyelination in MS

An antihistamine drug sold over the counter in the USA may remyelinate axons damaged by multiple sclerosis (MS), a Lancet study shows.

Patients with optic neuritis taking the drug, clemastine fumarate, demonstrated an improvement in signalling from the retina to the visual cortex as measured by a standard diagnostic test for MS (P100 latency of visual-evoked potentials).

The modest improvement of 1.7 milliseconds per eye was reported in patients taking the drug for 2-3 months, the US authors reported.

The patients in the trial had relapsing MS with a mean duration of five years, had